SPERO THERAPEUTICS INC (SPRO)
US84833T1034 - Common Stock
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending...
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with...
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active...
SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024
SPRO stock results show that Spero Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spero Therapeutics (NASDAQ:SPRO) just reported results for the second quarter o...
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD);...
Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...
3 Micro-Cap Moonshots for Fearless Investors
Investors should know the risks of micro-cap stocks before looking into these three high-potential companies with low prices.
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...
SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024
SPRO stock results show that Spero Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spero Therapeutics (NASDAQ:SPRO) just reported results for the first quarter of...
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected...
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of all the biggest pre-market stock movers worth watching on Thursday morning!
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected...
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...
Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...
Spero Therapeutics Provides Corporate Update and 2024 Outlook
In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
$95 million in development milestones payable over two years, as part of GSK license agreement...
